David Einhorn Stock Portfolio: Top 10 Stock Picks
David Einhorn of Greenlight Capital manages a 13F portfolio that was worth more than $2.8 billion at the end of the fourth quarter of 2025.
Teva Pharmaceutical Industries Ltd (TEVA)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Bourgeon Capital John Zaro | 286,257 | $8,622,061 | -54% | 1.49% |
| 2. | Bayforest Capital Theodoros Tsagaris | 1,455 | $43,825 | 0.05% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $18.86 | 1,113 | $20,988.06 | 13,027 | 2025-09-05 | Filing | |
| $9.60 | 104,500 | $1,003,409.00 | 220,442 | 2019-06-04 | Filing | |
| $8.98 | 111,000 | $997,013.10 | 115,942 | 2019-06-03 | Filing | |
| $21.92 | 2,000 | $43,840.00 | 6,445 | 2018-08-03 | Filing | |
| $19.32 | 250,000 | $4,829,700.00 | 1,500,000 | 2018-05-10 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $30.14 | 62,102 | $1,871,816.38 | 224,940 | 2026-03-17 | Filing | |
| $31.67 | 20,025 | $634,159.71 | 1,170,639 | 2026-03-05 | Filing | |
| $31.67 | 7,924 | $250,940.40 | 84,905 | 2026-03-05 | Filing | |
| $31.67 | 9,533 | $301,894.86 | 107,711 | 2026-03-05 | Filing | |
| $31.67 | 17,295 | $547,704.98 | 85,755 | 2026-03-05 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 142,344 | $4,287,401 | 0.09% | |
| 2. | 134,465 | $4,050,048 | 0.07% | |
| 3. | 124,086 | $3,737,470 | 0.02% | |
| 4. | 104,420 | $3,145,130 | 1.73% | |
| 5. | 93,150 | $2,805,678 | 1.29% |
News See All
8 Cheap Large Cap Stocks to Buy Now
Cheap large-cap stocks are getting more attention as investors are looking past the market’s most crowded winners and are now putting more weight on the current entry points.
Billionaire Stan Druckenmiller's 10 Small and Mid-Cap Stock Picks with Huge Upside Potential
Stanley Druckenmiller, the chief of New York-based investment firm Duquesne Capital, oversees a 13F portfolio at his hedge fund that was worth close to $4.5 billion at the end of the fourth quarter of...
Factors Supporting Teva Pharmaceutical's (TEVA) Long-Term Profitability
TCW funds, an investment management company, released its “TCW Relative Value Mid Cap Fund” fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here.
13 Cheapest Strong Buy Stocks to Buy Right Now
Buying stocks with a low forward Price-to-Earnings (P/E) ratio is a classic value-investing approach centered on identifying companies that may be undervalued relative to their expected future earnings...
Is Teva Pharmaceutical Industries (TEVA) A Good Stock To Buy Now?
Is TEVA a good stock to buy? We came across a bullish thesis on Teva Pharmaceutical Industries Limited on Kontra Investments’s Substack by Kontra.
Where is Teva Pharmaceutical Industries Limited (TEVA) Headed?
Teva Pharmaceutical Industries Limited (NYSE:TEVA) is one of the best strong buy healthcare stocks to invest in.
11 Best Strong Buy Healthcare Stocks to Invest In
On February 23, Steven Wieting, CIO Group chief investment strategist, appeared on CNBC’s ‘The Exchange’ to talk about the stock market and the recent price action in stocks.
Truist Boosts Teva (TEVA) Stock Target Amid Pipeline Growth Opportunities
Teva Pharmaceutical Industries Limited (NYSE:TEVA) ranks among billionaire Stanley Druckenmiller’s 10 best stock picks.
Goldman Sachs See Teva Pharmaceutical Industries Limited (TEVA) Driving Double-Digit Earnings Growth Through 2026
TheFly reported on February 9 that Goldman Sachs raised its price target on TEVA to $45 from $36, and gave it a Buy rating.
Hedge Fund Resource Center